|
|
Kaletra (Lopinavir/Ritonavir)
| Brand Name: |
Kaletra |
| Generic Name: |
Lopinavir/Ritonavir, LPV/RTV |
| Adult Single Dose*: |
Two tablets (400 mg/100 mg) twice daily or 4 tablets (800 mg/200 mg) once daily |
| Food & Liquid Restrictions: |
Take with or without food. Side effects may be lessened with food. |
| Drug Class: |
PI |
| * This recommendation is for patients starting HIV treatment. A different dose is recommended for treatment experienced patients. |
The Basics
- An Overview of Kaletra (Lopinavir/Ritonavir) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health
- Lopinavir + Ritonavir (Kaletra) (August 22, 2009)
To read PDF, click here
From AIDS InfoNet
- Medication Guide for Kaletra (April 6, 2009)
Created by the makers of Kaletra specifically for people with HIV. Includes a rundown of possible side effects, reasons why Kaletra may not be a good fit for everybody, meds to avoid while taking Kaletra, and tips on how to maximize the chances Kaletra will work well.
From Abbott Laboratories
- Kaletra (March/April 2009)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
- Patient Information About Kaletra (Lopinavir/Ritonavir) Tablets and Oral Solution (PDF) (April 2009)
From Abbott Laboratories
- Patient Frequently Asked Questions (November 2007)
Information about the new Kaletra (lopinavir/ritonavir) tablets.
From Abbott Laboratories
- Kaletra (Lopinavir/Ritonavir) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- Patient Information About Kaletra (Lopinavir/Ritonavir) Capsules (PDF) (July 2007)
From Abbott Laboratories
- Lopinavir (Kaletra) (August 15, 2006)
From AIDS Treatment Data Network
News
- FDA Warns Abbott on Magic Johnson DVD for HIV Drug (July 23, 2009)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Labeling Changes for Kaletra Reflecting New QT/QTC Interval and PR Interval Prolongation Information (April 7, 2009)
HIVers who have "electrical" problems with their heart -- problems that impact their heart rhythm, for instance -- should be wary of using Kaletra (lopinavir/ritonavir), according to new information added to the drug's official labeling.
From U.S. Food and Drug Administration
- WHO Approves Heat-Stable, Generic Version of Abbott's Kaletra (February 26, 2009)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Abbott Drug Pricing Condemned by AIDS Advocates in International Protests (January 27, 2009)
In coordinated actions, protesters in Mexico, Colombia and the U.S. demand that Abbott lowers the price of its key AIDS drug Kaletra; advocates otherwise vow to seek compulsory licenses in Colombia and Mexico; in U.S., AHF to also premiere 60-second video parody blasting Abbott and CEO Miles White on YouTube and place spot as TV commercial on select Chicago-area television stations.
From AIDS Healthcare Foundation
- New Pediatric Dosing Information for Kaletra, Patients 14 Days to 6 Months and 12-18 Years of Age and Update Information on Coadministration With Midazolam (PDF) (June 23, 2008)
From U.S. Food and Drug Administration
- Newly-Unsealed Documents Shed Light on Abbott Labs' 400% Norvir Price Hike (May 12, 2008)
Union, consumer groups decry Abbott for putting profits before HIV/AIDS patients' needs
In A Closer Walk: A Film by Robert Bilheimer, from Community Catalyst
- Abbott Receives FDA Approval for Lower-Dose of Kaletra for Children (November 13, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Kaletra and Accidental Overdose in Children (PDF) (August 16, 2007)
Direct Healthcare Professional communication on Kaletra (lopinavir/ritonavir) solution and accidental overdose in children.
From Abbott Laboratories
- Abbott, FDA Warn About Possible Overdose of Antiretroviral Kaletra in Children (August 15, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Student Global AIDS Campaign Responds to Abbott's Decision to Reduce Price of Kaletra in Low and Middle Income Countries (April 10, 2007)
From Student Global AIDS Campaign
Research
- Kaletra and Gemfibrozil (Lopid): A Match Not Made in Lipid Heaven (August 19, 2009)
Researchers have found that Lopid may not work as well in people who are taking the HIV medication Kaletra (lopinavir/ritonavir). But what does this finding actually mean for people with HIV?
From The Body
- Jens Lundgren, M.D., Discusses New Findings Regarding MI Risk of Specific Antiretrovirals (February 9, 2009)
The latest data from D:A:D indicate that lopinavir/ritonavir does increase myocardial infarction risk, but efavirenz, nevirapine and tenofovir do not. In this interview, Jens Lundgren, M.D., and HIV advocate Jeff Berry take part in a fascinating discussion on the new findings and their possible underlying causes.
In The 16th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Does Kaletra Monotherapy Work? Depends on Who You Ask (October 27, 2008)
Project Inform says the latest findings on Kaletra monotherapy are anything but positive.
From Project Inform
- Drug/Drug Interaction Between Lopinavir/Ritonavir and Rosuvastatin in Healthy Volunteers. (February 14, 2008)
In Journal of Acquired Immune Deficiency Syndromes
- Atazanavir Noninferior to Lopinavir in Treatment-Naive HIV-Infected People (February 6, 2008)
From The Body PRO
- Lopinavir/Ritonavir Monotherapy or Plus Zidovudine and Lamivudine in Antiretroviral-Naive HIV-Infected Patients (January 30, 2008)
In AIDS
- EACS: Kaletra Monotherapy May Need Excellent Adherence to Work (October 31, 2007)
In aidsmap.com
- ATAZIP: Switching Away From Lopinavir/Ritonavir (July 25, 2007)
Switching from lopinavir/ritonavir (Kaletra) to atazanavir (Reyataz)/ritonavir (Norvir) maintains virologic efficacy and leads to sustained improvements in lipid levels. Graeme Moyle, M.D., reports.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
- Darunavir Superior to Lopinavir in 48-Week Study in Treatment-Experienced Patients (July 6, 2007)
From aidsmap.com
- Kaletra-Based Regimens May Suppress Viral Load Despite Missed Doses (May 1, 2007)
In Journal of Acquired Immune Deficiency Syndromes
- Metabolic Complications: A CROI Round-Up (February 28, 2007)
Includes an analysis of research examining lopinavir/ritonavir vs. efavirenz, the use of growth hormone releasing factor to treat fat gain, the link between cardiovascular disease and HIV treatment, the use of ezetimibe (a choleserol-reducing agent) and the latest on bone health in HIV-infected patients.
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Predictors of Virologic Rebound on Lopinavir/Ritonavir Monotherapy (February 28, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Resistance Analysis of Lopinavir/Ritonavir Maintenance Therapy Study (February 27, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- The GEMINI Study: Are Saquinavir + Ritonavir and Lopinavir/Ritonavir Twins? (November 16, 2006)
In 8th International Congress on Drug Therapy in HIV Infection
- Long-Term Lopinavir/Ritonavir Treatment and CD4+ Cell Responses (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Reducing the Dose of Lopinavir/Ritonavir Is Associated With Low-Level Viremia (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Potency of Boosted Fosamprenavir Matches Lopinavir/Ritonavir for First-Line Therapy (August 17, 2006)
In XVI International AIDS Conference
- Switching From Lopinavir/Ritonavir to Unboosted Atazanavir May Yield Benefits, but Verdict Remains Uncertain (August 17, 2006)
In XVI International AIDS Conference
- Treating Patients With Lopinavir/Ritonavir Alone Still Risky (August 17, 2006)
In XVI International AIDS Conference
- Acid-Reducing Agents Reduce Atazanavir Drug Levels but Not Lopinavir/Ritonavir Levels (February 7, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections
- During the Third Trimester of Pregnancy Lopinavir/Ritonavir Dose Should Be Increased, Study Finds (February 6, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections
- Dosing Agenerase + Kaletra -- Trying to Juggle, Walk and Chew Gum All at the Same Time (March/April 2004)
A study presented at CROI 2004 bolsters support for the use of therapeutic drug monitoring to customize dosing.
In Positively Aware, from Test Positive Aware Network
|
Advertisement
|
E-Mail
Glossary
Share